|Slideshows|July 18, 2018

Geriatric Psychiatry Research: Herpesviruses, Brain Metals, DBS

New research suggests that viruses and metals in the brain may exacerbate Alzheimer disease and deep brain stimulation shows promise in slowing cognitive decline.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Week in Review: October 20-24

ByJessica Walters

October 24th 2025

Tardive Dyskinesia in Older Adults: Identification and Management in Long-Term Care Settings

ByAmita R. Patel, MD, CMD, MHA, CPE

October 23rd 2025

Rights and Risks in Geriatric Capacity Assessment

ByKaren Reimers, MD

October 22nd 2025

Insomnia in Older Adults: A Holistic Approach

ByEbony Dix, MD,Shilpa Srinivasan, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

October 21st 2025

Precision Diagnosis: The New Paradigm for Neurocognitive Disorders

BySehba Husain-Krautter MD, PhD,James M. Ellison, MD, MPH

October 20th 2025

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Geriatric Psychiatry Research: Herpesviruses, Brain Metals, DBS

Newsletter

Related Content

Week in Review: October 20-24

Tardive Dyskinesia in Older Adults: Identification and Management in Long-Term Care Settings

Rights and Risks in Geriatric Capacity Assessment

Insomnia in Older Adults: A Holistic Approach

Precision Diagnosis: The New Paradigm for Neurocognitive Disorders

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State

Data Presentation on XPro1595 for Alzheimer Disease With Inflammation at CTAD

Delay on Cobenfy Alzheimer Disease Psychosis Data Following Phase 3 Study “Irregularities,” New Patients Enrolled